Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.41 |
| ▸ | MME | P08473 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL447830 | 0.86 | MAPK1 (0.46) | MAPK1ALDH1A1LMNAMMEMAPT | |
| SCHEMBL7166167 | 0.81 | GAA (0.49) | MAPK1ALDH1A1SMN1; SMN2USP2LMNA | |
| SCHEMBL9465836 | 0.79 | ALDH1A1 (0.52) | MAPK1ALDH1A1SMN1; SMN2USP2LMNA | |
| SCHEMBL25832177 | 0.79 | ALDH1A1 (0.48) | MAPK1ALDH1A1SMN1; SMN2USP2LMNA | |
| SCHEMBL28841070 | 0.72 | MME (0.44) | MAPK1ALDH1A1SMN1; SMN2LMNAMME | |
| SCHEMBL9140305 | 0.72 | MEP1B (0.50) | ALDH1A1SMN1; SMN2LMNAMAPTKMT2A | |
| SCHEMBL447379 | 0.72 | MME (0.45) | MAPK1SMN1; SMN2MMEHPGDNPC1 | |
| SCHEMBL6523 | 0.72 | MME (0.40) | MAPK1ALDH1A1SMN1; SMN2MMEMAPT | |
| Gabapentin SCHEMBL3166322 | 0.71 | ALDH1A1 (0.54) | MAPK1ALDH1A1SMN1; SMN2USP2LMNA | |
| SCHEMBL28840772 | 0.71 | MME (0.46) | MAPK1ALDH1A1SMN1; SMN2LMNAMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. | 2012-03-15 | — | — | US | disclosed |
| WO-2011123674-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. (US) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | APP, BACE1, PSEN1 | MAPK1 1699/4885ALDH1A1 878/4885SMN1; SMN2 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.